(ROIV) Roivant Sciences - Ratings and Ratios
Antibody, Small-Molecule, Inhaled, Platform
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 35.2% |
| Value at Risk 5%th | 53.0% |
| Relative Tail Risk | -8.41% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.91 |
| Alpha | 63.20 |
| CAGR/Max DD | 0.83 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.488 |
| Beta | 0.740 |
| Beta Downside | 0.532 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.47% |
| Mean DD | 13.70% |
| Median DD | 13.84% |
Description: ROIV Roivant Sciences November 05, 2025
Roivant Sciences Ltd. (NASDAQ: ROIV) is a London-based, clinical-stage biopharma that builds and advances drug candidates through its own discovery engine and platform technologies. Its current pipeline centers on three monoclonal antibodies-IMVT-1402 (targeting the neonatal Fc receptor for a range of autoimmune disorders), batoclimab (for thyroid eye disease), and brepocitinib (a TYK2/JAK1 inhibitor for rare inflammatory conditions)-and a lead inhaled small-molecule, mosliciguat, aimed at pulmonary hypertension linked to interstitial lung disease. The firm also leverages lipid-nanoparticle (LNP) and ligand-conjugate delivery platforms to accelerate development.
From recent filings, Roivant reported a cash runway of roughly $1.2 billion through mid-2025, with R&D spending running at ~ $350 million in the latest fiscal year-indicative of a capital-intensive, yet well-funded, growth trajectory. The autoimmune market is expanding at a CAGR of ~ 8 % driven by unmet patient needs and premium pricing, which underpins the commercial upside of its antibody programs. Additionally, the company’s partnership network (e.g., a 2023 collaboration with Takeda on mosliciguat) provides non-dilutive funding and de-risking of late-stage trials.
For a deeper, data-driven view of Roivant’s valuation dynamics, you may find ValueRay’s analyst toolkit useful for uncovering hidden catalysts and risk factors.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-374.0m TTM) > 0 and > 6% of Revenue (6% = 1.22m TTM) |
| FCFTA -0.15 (>2.0%) and ΔFCFTA -2.91pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 21.5k% (prev 14.2k%; Δ 7377 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.15 (>3.0%) and CFO -769.9m <= Net Income -374.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 33.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (680.9m) change vs 12m ago -7.41% (target <= -2.0% for YES) |
| Gross Margin 96.41% (prev 92.20%; Δ 4.21pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.36% (prev 0.60%; Δ -0.24pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -7.30 (EBITDA TTM -996.9m / Interest Expense TTM -137.4m) >= 6 (WARN >= 3) |
Altman Z'' 2.53
| (A) 0.86 = (Total Current Assets 4.51b - Total Current Liabilities 133.9m) / Total Assets 5.06b |
| (B) -0.08 = Retained Earnings (Balance) -429.1m / Total Assets 5.06b |
| (C) -0.18 = EBIT TTM -1.00b / Avg Total Assets 5.63b |
| (D) -1.59 = Book Value of Equity -409.5m / Total Liabilities 257.1m |
| Total Rating: 2.53 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 31.89
| 1. Piotroski 2.0pt |
| 2. FCF Yield -7.26% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.02 |
| 5. Debt/Ebitda 1.14 |
| 6. ROIC - WACC (= -31.32)% |
| 7. RoE -8.05% |
| 8. Rev. Trend -61.69% |
| 9. EPS Trend 58.60% |
What is the price of ROIV shares?
Over the past week, the price has changed by -0.09%, over one month by +2.95%, over three months by +32.90% and over the past year by +87.75%.
Is ROIV a buy, sell or hold?
- Strong Buy: 6
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ROIV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 26.2 | 21.1% |
| Analysts Target Price | 26.2 | 21.1% |
| ValueRay Target Price | 28.6 | 32.5% |
ROIV Fundamental Data Overview January 03, 2026
P/S = 742.396
P/B = 3.4597
Beta = 1.227
Revenue TTM = 20.3m USD
EBIT TTM = -1.00b USD
EBITDA TTM = -996.9m USD
Long Term Debt = 98.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 9.00m USD (from shortTermDebt, last quarter)
Debt = 98.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.14b USD (from netDebt column, last quarter)
Enterprise Value = 10.81b USD (15.09b + Debt 98.8m - CCE 4.39b)
Interest Coverage Ratio = -7.30 (Ebit TTM -1.00b / Interest Expense TTM -137.4m)
FCF Yield = -7.26% (FCF TTM -784.4m / Enterprise Value 10.81b)
FCF Margin = -3858 % (FCF TTM -784.4m / Revenue TTM 20.3m)
Net Margin = -1840 % (Net Income TTM -374.0m / Revenue TTM 20.3m)
Gross Margin = 96.41% ((Revenue TTM 20.3m - Cost of Revenue TTM 729.0k) / Revenue TTM)
Gross Margin QoQ = 92.93% (prev 92.90%)
Tobins Q-Ratio = 2.13 (Enterprise Value 10.81b / Total Assets 5.06b)
Interest Expense / Debt = 13.56% (Interest Expense 13.4m / Debt 98.8m)
Taxrate = -4.40% (negative due to tax credits) (7.00m / -159.0m)
NOPAT = -1.05b (EBIT -1.00b * (1 - -4.40%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 33.70 (Total Current Assets 4.51b / Total Current Liabilities 133.9m)
Debt / Equity = 0.02 (Debt 98.8m / totalStockholderEquity, last quarter 4.36b)
Debt / EBITDA = 1.14 (negative EBITDA) (Net Debt -1.14b / EBITDA -996.9m)
Debt / FCF = 1.45 (negative FCF - burning cash) (Net Debt -1.14b / FCF TTM -784.4m)
Total Stockholder Equity = 4.65b (last 4 quarters mean from totalStockholderEquity)
RoA = -7.39% (Net Income -374.0m / Total Assets 5.06b)
RoE = -8.05% (Net Income TTM -374.0m / Total Stockholder Equity 4.65b)
RoCE = -21.14% (EBIT -1.00b / Capital Employed (Equity 4.65b + L.T.Debt 98.8m))
RoIC = -22.54% (negative operating profit) (NOPAT -1.05b / Invested Capital 4.65b)
WACC = 8.78% (E(15.09b)/V(15.19b) * Re(8.74%) + D(98.8m)/V(15.19b) * Rd(13.56%) * (1-Tc(-0.04)))
Discount Rate = 8.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -10.20%
Fair Price DCF = unknown (Cash Flow -784.4m)
EPS Correlation: 58.60 | EPS CAGR: 21.70% | SUE: 2.32 | # QB: 2
Revenue Correlation: -61.69 | Revenue CAGR: -51.85% | SUE: -0.12 | # QB: 0
EPS current Year (2026-03-31): EPS=-1.09 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=-27.2% | Growth Revenue=-45.1%
EPS next Year (2027-03-31): EPS=-1.13 | Chg30d=+0.060 | Revisions Net=+1 | Growth EPS=-3.6% | Growth Revenue=+641.1%
Additional Sources for ROIV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle